Biotech Odyssey, Medical Device Firm Mobia File for US IPOs

Two healthcare firms—a drug developer and a medical device maker—filed for U.S. IPOs in April 2026, joining a wave of biotech companies pursuing public listings amid strong market conditions. Biotech Odyssey, an autoimmune and inflammatory disease-focused developer, leads the push, signaling investor confidence in specialized therapeutic sectors. Mobia, a medical device company, simultaneously submitted its IPO paperwork, expanding the pipeline of healthcare tech firms targeting public markets this year. The filings reflect broader biotech sector momentum, with robust demand for innovative treatments and diagnostics driving valuation optimism among underwriters. Analysts note the IPO surge aligns with post-pandemic recovery trends, as healthcare innovation remains a top priority for institutional and retail investors alike.